Patents by Inventor Kevin Sheth

Kevin Sheth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220168230
    Abstract: At least five classes of MNP-based compounds have been demonstrated to form supramolecular particles for effective delivery by injection or topically of different types of therapeutic, prophylactic, or diagnostic agents. These compounds are isolated from natural sources such as plants. Exemplary MNP-based compounds, from which synthetic analogs or derivatives are made and appreciated to function similarly, e.g., capable of forming supramolecular particles include diterpene resin acids (e.g., abietic acid and pimaric acid), phytosterols (e.g., stigmasterol and ?-sitosterol), lupane-type pentacyclic triterpenes (e.g., lupeol and betulinic acid), oleanane-type pentacyclic tritepenes (e.g., glycyrrhetic acid and sumaresinolic acid), and lanostane-type triterpenes and derivatives (e.g., dehydrotrametenolic acid and poricoic acid A). In some cases the MNP-based compounds are therapeutically effective in the absence of added therapeutic, prophylactic or diagnostic agent.
    Type: Application
    Filed: February 26, 2020
    Publication date: June 2, 2022
    Inventors: Jiangbing Zhou, Kevin Sheth, Gang Deng, Shenqi Zhang, Zeming Chen, Chao Ma
  • Patent number: 6984484
    Abstract: High levels of D-serine occur in mammalian brain, where it appears to be an endogenous ligand of the “glycine site” of NMDA receptors. We have purified from rat brain a soluble enzyme that catalyzes the direct racemization of L-serine to D-serine. Purified serine racemase has a molecular weight of 37 kDa and requires pyridoxal 5?-phosphate for its activity. The enzyme is highly selective toward L-serine, failing to racemize any other amino acid tested. We have also identified polynucleotide sequences that encode mammalian, including human, serine racemase. Compounds that modulate the activity of mammalian serine racemase are useful for treating conditions and diseases that involve overstimulation of NMDA receptors, such as stroke and various neurodegenerative diseases.
    Type: Grant
    Filed: January 18, 2000
    Date of Patent: January 10, 2006
    Assignee: The Johns Hopkins University
    Inventors: Soloman H. Snyder, Herman Wolosker, Kevin Sheth, Takahashi Masaaki, Jean-Pierre Mothet, Roscoe Brady, Jr., Christopher D. Ferris